Literature DB >> 31081578

Landscape of microRNA in the aqueous humour of proliferative diabetic retinopathy as assessed by next-generation sequencing.

Shida Chen1, Miner Yuan1, Yaoming Liu1, Xiujuan Zhao1, Ping Lian1, Yang Chen1, Bingqian Liu1, Lin Lu1.   

Abstract

BACKGROUND: The microRNAs (miRNA) have been found to play an important role in the pathogenesis of diabetic retinopathy. We try to explore the miRNA and piwi-interacting RNA (piRNA) profile in the aqueous humour of proliferative diabetic retinopathy (PDR) using next-generation sequencing (NGS).
METHODS: Aqueous humour samples were collected from nine PDR eyes and nine cataract control eyes, and NGS was performed. Quantitative polymerase chain reaction (qPCR) was used to validate the sequencing results. An oxygen-induced retinopathy (OIR) model was used to validate the angiogenesis related miRNA.
RESULTS: In total, 484 miRNAs were differently expressed between the PDR eyes and cataract control eyes, including 210 mature miRNAs and 274 novel miRNAs. Furthermore, eight miRNAs and 30 piRNAs were identified as the most differently expressed between the two groups (P > .85). This differential expression of miRNA was predicted to regulate Rho protein signal transduction, neurotransmitter uptake and histone lysine methylation. Relative expression patterns of miR-184, -150-5p and -93-5p were confirmed by qPCR. A reduced expression of miR-93-5p was confirmed in the OIR model.
CONCLUSIONS: This study comprehensively demonstrated the miRNA and piRNA expression profile of the aqueous humour of PDR eyes, which may serve as a potential biomarker and involved in the pathogenesis of PDR.
© 2019 Royal Australian and New Zealand College of Ophthalmologists.

Entities:  

Keywords:  biomarker; microRNA; next-generation sequencing; piwi-interacting RNA; proliferative diabetic retinopathy

Year:  2019        PMID: 31081578     DOI: 10.1111/ceo.13554

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  7 in total

Review 1.  Application Progress of High-Throughput Sequencing in Ocular Diseases.

Authors:  Xuejun He; Ningzhi Zhang; Wenye Cao; Yiqiao Xing; Ning Yang
Journal:  J Clin Med       Date:  2022-06-17       Impact factor: 4.964

2.  Identification of Diagnostic and Prognostic microRNAs for Recurrent Vitreous Hemorrhage in Patients with Proliferative Diabetic Retinopathy.

Authors:  Parviz Mammadzada; Juliette Bayle; Johann Gudmundsson; Anders Kvanta; Helder André
Journal:  J Clin Med       Date:  2019-12-15       Impact factor: 4.241

3.  Decreased Levels of miR-126 and miR-132 in Plasma and Vitreous Humor of Non-Proliferative Diabetic Retinopathy Among Subjects with Type-2 Diabetes Mellitus.

Authors:  Subhasish Pramanik; Chinmay Saha; Subhankar Chowdhury; Chiranjit Bose; Nitai P Bhattacharyya; Lakshmi Kanta Mondal
Journal:  Diabetes Metab Syndr Obes       Date:  2022-02-04       Impact factor: 3.168

Review 4.  Research progress on exosomes/microRNAs in the treatment of diabetic retinopathy.

Authors:  Si-Ru Niu; Jian-Min Hu; Shu Lin; Yu Hong
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-09       Impact factor: 6.055

Review 5.  Potential epigenetic molecular regulatory networks in ocular neovascularization.

Authors:  Qiang Hu; Xue Zhang; Minghao Sun; Bo Jiang; Zhongyu Zhang; Dawei Sun
Journal:  Front Genet       Date:  2022-09-02       Impact factor: 4.772

6.  MiR-221/SIRT1/Nrf2 signal axis regulates high glucose induced apoptosis in human retinal microvascular endothelial cells.

Authors:  Bin Chen; Li Wu; Ting Cao; Hong-Mei Zheng; Tao He
Journal:  BMC Ophthalmol       Date:  2020-07-22       Impact factor: 2.209

7.  MicroRNA Expression in the Aqueous Humor of Patients with Diabetic Macular Edema.

Authors:  Giuseppina Emanuela Grieco; Guido Sebastiani; Chiara Maria Eandi; Giovanni Neri; Laura Nigi; Noemi Brusco; Romina D'Aurizio; Matteo Posarelli; Tommaso Bacci; Elena De Benedetto; Mario Fruschelli; Maurizio Orlandini; Federico Galvagni; Francesco Dotta; Gian Marco Tosi
Journal:  Int J Mol Sci       Date:  2020-10-03       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.